Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder;Vergleich der effektivität der langzeitinstillation mit mitomycin C gegen kurzzeitprophylaxen mit MMC oder bacillus Calmette-Guerin. Untersuchung bei patienten mit nicht muskelinvasivem urothelkarzinom der harnblase

Urologe - Ausgabe A

Volumn 47, Issue 5, 2008, Pages 608-615

  Isbarn, H ^a   Budaus L ^a   Pichlmeier, U ^b   Conrad, S ^a,c   Huland, H ^a   Friedrich, M G ^a,d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MEDAC GMBH   (Germany)

^c Friederikenstift   (Germany)

^d HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

BCG; Mitomycin C; Non muscle invasive urinary bladder cancer; Recurrence

Indexed keywords

BCG VACCINE; MITOMYCIN C;

ARTICLE; BLADDER CANCER; CANCER PATIENT; CANCER PREVENTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INSTILLATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SHORT COURSE THERAPY; TRANSURETHRAL RESECTION; URINARY TRACT CANCER; UROTHELIUM CANCER;

EID: 44149085889     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-008-1671-z     Document Type: Article

References (24)

1. 1. Chopin 2002 Eur Urol 42 533 12477647 10.1016/S0302-2838(02)00466-9 Chopin DK, Gattegno B (2002) Superficial bladder tumors. Eur Urol 42: 533–541
2. 2. Sylvester 2006 Eur Urol 49 466 16442208 10.1016/j.eururo.2005.12.031 Sylvester RJ, Meijden AP van der, Oosterlinck W et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466–477
3. 3. Millan-Rodriguez 2000 J Urol 163 73 10604317 10.1016/S0022-5347(05)67975-X 1:STN:280:DC%2BD3c%2FmslyjtA%3D%3D Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J et al. (2000) Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163: 73–78
4. 4. Smith 1999 J Urol 162 1697 10524909 10.1016/S0022-5347(05)68208-0 Smith JA Jr, Labasky RF, Cockett AT et al. (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162: 1697–1701
5. 5. Huland 1990 J Urol 144 68 2113590 1:STN:280:By%2BB1MvjvVE%3D Huland H, Kloppel G, Feddersen I et al. (1990) Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol 144: 68–72
6. 6. Bouffioux 1995 J Urol 153 934 7853578 10.1016/S0022-5347(01)67608-0 1:STN:280:ByqC2MnmslI%3D Bouffioux C, Kurth KH, Bono A et al. (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 EORTC randomized trials with Mitomycin C and doxurubicin comparing early vs, delayed instillations and short-term vs. long-term treatment. EORTC Genitourinary Group. J Urol 153: 934–941
7. 7. Malmström 1999 J Urol 161 1124 10081852 10.1016/S0022-5347(01)61607-0 Malmström PU, Wijkström H, Lundholm C et al. (1999) 5-year followup of a randomized prospective study comparing Mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161: 1124–1127
8. 8. Krege 1996 J Urol 156 962 8709374 10.1016/S0022-5347(01)65673-8 1:STN:280:BymA38%2FpsVE%3D Krege S, Giani G, Meyer R et al. (1996) A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only vs. transurethral resection plus Mitomycin C vs. transurethral resection plus bacillus Calmette-Guerin. J Urol 156: 962–966
9. 9. Oosterlinck 2002 Prog Urol 12 1161 12536941 1:STN:280:DC%2BD3s%2FjtVCjtw%3D%3D Oosterlinck W, Lobel B, Jackse G et al. (2002) EAU Recommendations 2001. „Guidelines on bladder cancer“. Prog Urol 12: 1161–1163
10. 10. Sylvester 2002 J Urol 168 1964 12394686 10.1016/S0022-5347(05)64273-5 1:CAS:528:DC%2BD38XotFKrsLg%3D Sylvester RJ, Meijden AP van der, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964–1970
11. 11. Böhle 2004 Urology 63 682 15072879 10.1016/j.urology.2003.11.049 Böhle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus Mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63: 682–687
12. 12. Böhle 2003 J Urol 169 90 12478111 10.1016/S0022-5347(05)64043-8 Böhle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus Mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169: 90–95
13. 13. Witjes 2006 Eur Urol 49 790 16464532 10.1016/j.eururo.2006.01.017 Witjes JA (2006) Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49: 790–797
14. 14. Sobin DHWC (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York
15. 15. Oosterlinck W, Meijden AP van der, Sylvester R et al. (2006) Guidelines on TaT1 (non-muscle invasive) bladder cancer. EAU Recommendations, Arnhem, Niederlande
16. 16. Huncharek 2004 Am J Clin Oncol 27 522 15596924 10.1097/01.coc.0000135570.37287.7f Huncharek M, Kupelnick B (2004) The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 27: 522–528
17. 17. Lundholm 1996 J Urol 156 372 8683682 10.1016/S0022-5347(01)65853-1 1:CAS:528:DyaK28XkvFart7Y%3D Lundholm C, Norlen BJ, Ekman P et al. (1996) A randomized prospective study comparing long-term intravesical instillations of Mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 156: 372–376
18. 18. Lamm 1995 Urol Oncol 1 119 Lamm DL, Blumenstein BA, Crawford ED et al. (1995) Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and Mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. A Sothwest Oncology Group Study. Urol Oncol 1: 119–124
19. 19. Evans 2003 BJU Int 92 345 12930415 10.1046/j.1464-410X.2003.04357.x 1:STN:280:DC%2BD3szptlaisA%3D%3D Evans CP, Busby JE (2003) The management of stage T1 grade 3 transitional cell carcinoma of the bladder. BJU Int 92: 345–348
20. 20. Lamm DL (1995) BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Huntingt) 9: 947–965
21. 21. Witjes 1998 Urology 52 403 9730451 10.1016/S0090-4295(98)00212-X 1:STN:280:DyaK1czpvVaiuw%3D%3D Witjes JA, Meijden AP van der, Collette L et al. (1998) Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and Mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52: 403–410
22. 22. Gardmark 2007 BJU Int 4 817 10.1111/j.1464-410X.2006.06706.x Gardmark T, Jahnson S, Wahlquist R et al. (2007) Analysis of progression and survival after 10 years of a randomized prospective study comparing Mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int 4: 817–820
23. 23. Au 2001 J Natl Cancer Inst 93 597 11309436 10.1093/jnci/93.8.597 1:CAS:528:DC%2BD3MXjsV2rur8%3D Au JL, Badalament RA, Wientjes MG et al. (2001) Methods to improve efficacy of intravesical Mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93: 597–604
24. 24. Sylvester 2004 J Urol 171 2186 15126782 10.1097/01.ju.0000125486.92260.b2 Sylvester RJ, Oosterlinck W, Meijden AP van der (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta, T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171: 2186–2435